PropertyGuru Lists on the NYSE
~US$254 million raised in public listing via completion of business combination with Bridgetown 2 with…
News
KBRA Assigns Preliminary Ratings to MSC 2022-L8
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA is pleased to announce the assignment of preliminary ratings to 38 classes…
UNESCO-Backed IRCAI Names Northeastern’s and UNAM’s Civic AI Research – in Collaboration with Toloka – as Most Impactful
Awarded the top project in the “A.I. For Good” category for their work in rural…
NTT DATA Research Reveals Executives are Challenged with How to Leverage Technology to Respond to Changing Customer Needs
Only 4 out of 10 organizations believe they are highly effective at delivering the kind…
Spintly Appoints Nuovations’ Grant Erickson as a Technology Advisor
Appointment Will Accelerate Introduction of Spintly Thread-based Wireless Access Control Solutions SAN JOSE, Calif.–(BUSINESS WIRE)–#Buildingaccesscontrol—Spintly,…
Signature Bank Announces Availability of Materials for 2022 Annual Shareholders’ Meeting and Special Meeting of Holders of Series A Preferred Stock
NEW YORK–(BUSINESS WIRE)–Signature Bank (Nasdaq:SBNY), a New York-based, full-service commercial bank, announced today the Bank’s…
SpartanNash Addresses Director Nominations
Macellum originally nominated a control slate while owning just 1,000 shares in December and prior…
Why Ransomware Attacks Steer Clear of the Cloud
Snyk Chief Architect Josh Stella Explains Why Attackers Aren’t Targeting Cloud Environments With Ransomware and…
All of Us Research Program Releases Genomic Data to Researchers, Combined with Participant-Generated Data Collected on Vibrent Health’s Digital Health Research Platform
Precision medicine initiative leverages innovative technologies and unprecedented 80% diverse participant base to drive new…
Nymox Announces $5 Million Registered Direct Offering
IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced…
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity
SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in…
Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences
– 5th Annual Neuroscience Innovation Forum – – BIO-Europe Spring® 2022 – CUPERTINO, Calif., March…
Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update
CARLSBAD, Calif., March 18, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the…
Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO’s Breast Cancer Congress 2022
SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris
Sanofi moves forward with EUROAPI listing on Euronext Paris Sanofi will give its shareholders…
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company…
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) — Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader…
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting
– Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the…
Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
– Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and…